Lyotropic liquid crystals for parenteral drug delivery

J Control Release. 2022 Sep:349:533-549. doi: 10.1016/j.jconrel.2022.06.062. Epub 2022 Jul 20.

Abstract

The necessity for long-term treatments of chronic diseases has encouraged the development of novel long-acting parenteral formulations intending to improve drug pharmacokinetics and therapeutic efficacy. Lately, one of the novel approaches has been developed based on lipid-based liquid crystals. The lyotropic liquid crystal (LLC) systems consist of amphiphilic molecules and are formed in presence of solvents with the most common types being cubic, hexagonal and lamellar mesophases. LC injectables have been recently developed based on polar lipids that spontaneously form liquid crystal nanoparticles in aqueous tissue environments to create the in-situ long-acting sustained-release depot to provide treatment efficacy over extended periods. In this manuscript, we have consolidated and summarized the various type of liquid crystals, recent formulation advancements, analytical evaluation, and therapeutic application of lyotropic liquid crystals in the field of parenteral sustained release drug delivery.

Keywords: Drug delivery; In situ phase transition; Liquid crystals; Lyotropic liquid crystals; Microemulsion; Parenteral delivery; Surfactant.

Publication types

  • Review

MeSH terms

  • Delayed-Action Preparations / chemistry
  • Drug Delivery Systems
  • Drug Liberation
  • Lipids / chemistry
  • Liquid Crystals* / chemistry
  • Nanoparticles*
  • Solvents

Substances

  • Delayed-Action Preparations
  • Lipids
  • Solvents